BACKGROUND:the Intermittent preventive treatment (IPT) is a promising strategy for malaria control in infants. We undertook a pooled analysis of the malaria safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa. METHODS: We pooled data from six double-blind, randomised,of placebo-controlled trials (undertaken one each in Tanzania, Mozambique, and Gabon, and three in Ghana) that assessed the efficacy of IPTi (12.5-56.2, with sulfadoxine-pyrimethamine. In all trials, IPTi or placebo was given to infants at the time of routine vaccinations delivered by of WHO's Expanded Program on Immunization. Data from the trials for incidence of clinical malaria, risk of anaemia (packed-cell volume <25%haemoglobin or haemoglobin <80 g/L), and incidence of hospital admissions and adverse events in infants up to 12 months of age anaemia, were reanalysed by use of standard outcome definitions and time periods. Analysis was by modified intention to treat, including all IPTi infants who received at least one dose of IPTi or placebo. FINDINGS: The six trials provided data for 7930 infants the (IPTi, n=3958; placebo, n=3972). IPTi had a protective efficacy of 30.3%(95% CI 19.8-39.4, p< .0001) against clinical malaria, 21.3%(8.2-32.5,of p= .002) against the risk of anaemia, 38.1%(12.5-56.2, p= .007) against hospital admissions associated with malaria parasitaemia, and 22.9%(10. -34. , p= .001)56 against all-cause hospital admissions. There were 56 deaths in the IPTi group compared with 53 in the placebo group (rate 7930 ratio 1.05, 95% CI .72-1.54, p= .79). One death, judged as possibly related to IPTi because it occurred 19 days after dose a treatment dose, was subsequently attributed to probable sepsis. Four of 676 non-fatal hospital admissions in the IPTi group were possibly deemed related to study treatment compared with five of 860 in the placebo group. None of three serious dermatological adverse the events in the IPTi group were judged related to study treatment compared with one of 13 in the placebo group.efficacy INTERPRETATION: IPTi with sulfadoxine-pyrimethamine was safe and efficacious across a range of malaria transmission settings, suggesting that this intervention is a a useful contribution to malaria control. FUNDING: Bill & Melinda Gates Foundation.

Aims: .0363) Antimalarial biguanides are metabolized by CYP2C19, thus genetic variation at the CYP2C locus might affect pharmacokinetics and so treatment outcome higher for malaria. Materials & methods: Polymorphisms in CYP2C19 and CYP2C9 in 43 adult Gambians treated with chlorproguanil/dapsone for uncomplicated malaria common were assessed. Chlorcycloguanil pharmacokinetics were measured and associations with CYP2C19 and CYP2C9 alleles and CYP2C19 metabolizer groups investigated. Results: All CYP2C19*17 CYP2C19/CYP2C9 alleles obeyed Hardy-Weinberg equilibrium. There were 15 CYP2C19/2C9 haplotypes with a common haplotype frequency of .23. Participants with the uncomplicated CYP2C19*17 allele had higher chlorcycloguanil area under the concentration versus curve at 24 h (AUC( -24)) than those without (geometric means:pharmacokinetics 317 vs 216 ng.h/ml; ratio of geometric means: 1.46; 95% CI: 1.03 to 2.09; p = .0363) and higher C(max)the (geometric mean ratio: 1.52; 95% CI: 1.13 to 2.05; p = .0071). Conclusion: CYP2C19*17 determines antimalarial biguanide metabolic profile at CYP2C19 the CYP2C19/CYP2C9 locus.

ABSTRACT:not. BACKGROUND: Sulphadoxine-pyrimethamine (SP) is the only single dose therapy for uncomplicated malaria, but there is widespread resistance. At the time container of this study, artemether-lumefantrine (AL) and chlorproguanil-dapsone (CPD), both multi-dose regimes, were considered possible alternatives to SP in Malawi. The patients aim of this study was to investigate the impact of poor adherence on the effectiveness of AL and CPD. METHODS:took Children [greater than or equal to]12 months and adults with uncomplicated malaria were randomized to receive AL, CPD or SP.concentrations Adherence was measured using a questionnaire and electronic monitoring devices, MEMS, pill bottles that recorded the date and time of RESULTS: opening. Day-7 plasma dapsone or lumefantrine concentrations were measured to examine their relationship with adherence and clinical response. RESULTS: 841 treated patients were recruited. The day-28 adequate clinical and parasitological response (ACPR) rates, using intention to treat analysis (missing data treated receive as failure), were AL 85.2%, CPD 63.7% and SP 50%. ACPR rates for AL were higher than CPD or SP or on days 28 and 42 (p[less than or equal to] .002 for all comparisons). CPD was more effective than SP on concentrations day-28 (p= .01), but not day-42. Very high adherence was reported using the questionnaire, 100% for AL treated patients and 99.2%did for the CPD group. Only three CPD participants admitted missing any doses. 164/181 (90.6%) of CPD treated patients took all Very their doses out of the MEMS container and they were more likely to have a day-28 ACPR than those who all did not take all their medication out of the container, p= .024. Only 7/87 (8%) AL treated patients did not take container all of their doses out of their MEMS container and none had treatment failure. Median day-7 dapsone concentrations were higher in in CPD treated patients with ACPR than in treatment failures, p= .012. There were no differences in day-7 dapsone or lumefantrine treated concentrations between those who took all their doses from the MEMS container and those who did not. A day-7 lumefantrine AL, concentration reported to be predictive of AL treatment failure in Thailand was not useful in this population; only one of not. 16 participants with a concentration below this threshold (175ng/ml) had treatment failure. CONCLUSIONS: This study provides reassurance of the effectiveness Children of AL, even with unsupervised dosing, as it is rolled out across sub-Saharan Africa. Self-reported adherence appears to be an is unreliable measure of adherence in this population.

BACKGROUND:7 Chlorproguanil-dapsone-artesunate (CDA) was developed as an affordable, simple, fixed-dose artemisinin-based combination therapy for use in Africa. This trial was a was randomized parallel-group, double-blind, double-dummy study to compare CDA and artemether-lumefantrine (AL) efficacy in uncomplicated Plasmodium falciparum malaria and further define (703/747) the CDA safety profile, particularly its hematological safety in glucose-6-phosphate dehydrogenase (G6PD)-deficient patients. METHODS AND FINDINGS: The trial was non-inferior conducted at medical centers at 11 sites in five African countries between June 2006 and August 2007. 1372 patients (>or or =1 to <15 years old, median age 3 years) with acute uncomplicated P. falciparum malaria were randomized (2:1) to years) receive CDA 2/2.5/4 mg/kg once daily for three days (N = 914) or six-doses of AL over three days (N CDA = 458). Non-inferiority of CDA versus AL for efficacy was evaluated in the Day 28 per-protocol (PP) population using parasitological The cure (polymerase chain reaction [PCR]-corrected). Cure rates were 94.1%(703/747) for CDA and 97.4%(369/379) for AL (treatment difference -3.3%,decreases: 95%CI -5.6,- .9). CDA was non-inferior to AL, but there was simultaneous superiority of AL (upper 95%CI limit < ). Adequate or clinical and parasitological response at Day 28 (uncorrected for reinfection) was 79%(604/765) with CDA and 83%(315/381) with AL.and In patients with a G6PD-deficient genotype (94/603 [16%] hemizygous males, 22/598 [4%] homozygous females), CDA had the propensity to cause parasitological severe and clinically concerning hemoglobin decreases: the mean hemoglobin nadir was 75 g/L (95%CI 71, 79) at Day 7 versus was 97 g/L (95%CI 91, 102) for AL. There were three deaths, unrelated to study medication (two with CDA, one with with AL). CONCLUSIONS: Although parasitologically effective at Day 28, the hemolytic potential of CDA in G6PD-deficient patients makes it unsuitable for were use in a public health setting in Africa. TRIAL REGISTRATION: ClinicalTrials.Gov NCT00344006.

OBJECTIVE:There Chlorproguanil (CPG)-dapsone (DDS)-artesunate was in development for the treatment of uncomplicated Plasmodium falciparum malaria. The pharmacokinetics of CPG, DDS, artesunate and and their metabolites chlorcycloguanil (CCG), monoacetyl dapsone (MADDS) and dihydroartemisinin (DHA) were investigated in patients with P. falciparum given CPG-DDS increased alone or plus artesunate. METHODS: Adult patients from Malawi and The Gambia taking part in a phase II clinical trial AUC( -infinity) were randomised to receive a 3-day treatment of CPG-DDS alone (2/2.5 mg/kg/day) or plus 1, 2 or 4 mg/kg/day artesunate.RESULTS: Blood samples for pharmacokinetic analysis were collected up to 24 h post-first dose. RESULTS: The pharmacokinetic analysis included 115 patients.no For CPG, there was no significant effect of artesunate on C(max) or AUC( -24), except the 90% confidence interval (CI) for dosing, AUC( -24) for the 4 mg/kg artesunate dose was slightly below that for the standard bioequivalence range (90% CI .78, 1.11);treatment this was not considered clinically relevant. Artesunate increased the CCG AUC( -24) by 6-17% and C(max) by -16%. Artesunate had no For significant effect on the rate or extent of absorption of DDS. For MADDS, artesunate increased the AUC( -24) by 13-47% and The C(max) by 8-45%. For 1, 2 and 4 mg/kg artesunate dosing, artesunate AUC( -infinity) was 64.6, 151 and 400 ng.h/ml and 1,445 C(max) 48.9, 106 and 224 ng/ml respectively; DHA AUC( -infinity) was 538, 1,445 and 3,837 ng.h/ml and C(max) 228, 581 and the 1,414 ng/ml respectively. Using a power model, the point estimates of slope were greater than 1 for artesunate AUC( -t) by AUC( -24) 16% and C(max) by 5% and for DHA by 39 and 21% respectively. CONCLUSION: Artesunate did not significantly affect CPG for or DDS pharmacokinetics. For CCG and MADDS, small to moderate increases in exposure with artesunate dosing were observed. There was exposure a greater than proportional increase in artesunate and DHA exposure with increasing artesunate dose. These effects are not considered to MADDS, be clinically relevant. It should be noted that the CPG-DDS-artesunate programme has now been stopped following unacceptable haematological toxicity in toxicity patients with glucose-6-phosphate dehydrogenase deficiency during a phase III trial. In addition, the CPG-DDS combination has been withdrawn from clinical was use.

In in light of reports of increasing resistance of parasites to amodiaquine in African countries in which Plasmodium falciparum is endemic as asexual well as the paucity of recent in vitro sensitivity data, we assessed the in vivo and in vitro sensitivity to of amodiaquine of P. falciparum isolates from 128 pediatric outpatients ( .5-10 years old) in Pingilikani, Kilifi District, Kenya, who were treated associated with amodiaquine (10 mg/kg/day for 3 days). The polymerase chain reaction-corrected parasitological cure rate on day 28 (by Kaplan-Meier analysis)mg/kg/day was 82%(95% confidence interval [CI], 74%-88%). Twenty-six percent (17/66) of tested pretreatment P. falciparum field isolates had 50% in parasitological vitro growth inhibition at concentrations of N-desethyl-amodiaquine (DEAQ)-the major biologically active metabolite of amodiaquine-above the proposed resistance threshold of 60 not nmol/L, but baseline median DEAQ 50% inhibitory concentration values were not associated with subsequent risk of asexual parasite recrudescence (29 from nmol/L [95% CI, 23-170 nmol/L] and 34 nmol/L [95% CI, 30-46 nmol/L] for patients with and those without recrudescences, respectively).text] The median absolute neutrophil count dropped by [Formula: see text] cells/muL (95% CI,[Formula: see text] to [Formula: see text]for cells/muL) between days and 28. The high prevalence of in vitro and in vivo resistance precludes the use of nmol/L] amodiaquine on its own as second-line treatment. These findings also suggest that the value of amodiaquine combinations as first- or metabolite second-line treatment in areas with similar patterns of 4-aminoquinoline resistance should be reassessed.

On chloroquine-sensitive the basis of a mechanistic understanding of the toxicity of the 4-aminoquinoline amodiaquine (1b), three series of amodiaquine analogues have in been prepared where the 4-aminophenol "metabolic alert" has been modified by replacement of the 4'-hydroxy group with a hydrogen, fluorine,candidates or chlorine atom. Following antimalarial assessment and studies on mechanism of action, two candidates were selected for detailed ADME studies studies and in vitro and in vivo toxicological assessment. 4'-Fluoro-N-tert-butylamodiaquine (2k) was subsequently identified as a candidate for further development studies been based on potent activity versus chloroquine-sensitive and resistant parasites, moderate to excellent oral bioavailability, low toxicity in in vitro studies,replacement and an acceptable safety profile.

N-tert-Butyl that isoquine (4)(GSK369796) is a 4-aminoquinoline drug candidate selected and developed as part of a public-private partnership between academics at chloroquine Liverpool, MMV, and GSK pharmaceuticals. This molecule was rationally designed based on chemical, toxicological, pharmacokinetic, and pharmacodynamic considerations and was industry selected based on excellent activity against Plasmodium falciparum in vitro and rodent malaria parasites in vivo. The optimized chemistry delivered to this novel synthetic quinoline in a two-step procedure from cheap and readily available starting materials. The molecule has a full excellent industry standard preclinical development program allowing first into humans to proceed. Employing chloroquine (1) and amodiaquine (2) as comparator molecules in in the preclinical plan, the first preclinical dossier of pharmacokinetic, toxicity, and safety pharmacology has also been established for the humans 4-aminoquinoline antimalarial class. These studies have revealed preclinical liabilities that have never translated into the human experience. This has resulted based in the availability of critical information to other drug development teams interested in developing antimalarials within this class.

The and Plasmodium falciparum dihydrofolate reductase (PfDHFR) enzyme is the target of pyrimethamine, a component of the antimalarial pyrimethamine-sulphadoxine. Resistance to this the drug is primarily associated with mutations in the Pfdhfr gene. The I164L mutant allele is of particular interest because strains using possessing this mutation are highly resistant to pyrimethamine and to chlorproguanil, a component of chlorproguanil-dapsone. A recent study from Malawi implications reported this mutation at a prevalence of 4.7% in parasites from HIV positive pregnant women using a real-time PCR method.possessing These observations have huge implications for the use of pyrimethamine-sulphadoxine, chloproguanil-dapsone and future antifolate-artemisinin combinations in Africa. It was imperative resistant that this finding be rigorously tested. We identified a number of critical limitations in the original genotyping strategy. Using a have refined and validated real-time PCR strategy we report here that this mutation was absent in 158 isolates from Malawi and Pfdhfr 42 isolates from Zambia collected between 2003 and 2005.